ImaginAb

ImaginAb clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.

ImaginAb’s mission is to transform the clinical management of cancer and autoimmune diseases via targeted molecular imaging. We re-engineer therapeutic antibodies against biologically important targets into small proteins optimized for diagnostic imaging with Positron Emission Tomography (PET). We believe that in the era of targeted molecular therapy, there is a major unmet need for true companion in vivo diagnostics to help realize the promise of personalized medicine. ImaginAb is developing imaging agents that have the potential to deliver fundamentally new clinical insights into diseases such as prostate cancer and Crohn’s disease. Our products offer precise and actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. Our technology platform is also being developed in partnership with select global pharmaceutical companies to develop “companion imaging agents” – imaging agents that provide real-time insight into the expression and availability of key therapeutic targets in patients with cancer and autoimmune diseases.